Sweden
· Delayed Price · Currency is SEK Xspray Pharma AB Company Description
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden.
The company’s product candidates include Dasynoc, a trailblazer, under approval phase for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib, under pivotal studies for the treatment of chronic myeloid leukemia; XS008, based on axitinib, under development for treatment of kidney cancer; and XS00Y under development phase.
It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa for commercial production of Dasynoc.
The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017.
Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.
| Country | Sweden |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Per Andersson |
Contact Details
Address: Scheeles väg 2 Solna, 171 65 Sweden | |
| Phone | 46 87 30 37 00 |
| Website | xspraypharma.com |
Stock Details
| Ticker Symbol | XSPRAY |
| Exchange | Nasdaq Stockholm |
| Reporting Currency | SEK |
| ISIN Number | SE0009973563 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Per Andersson Ph.D. | Chief Executive Officer |
| Dr. Mustafa Demirbüker Ph.D. | Co-Founder and Science Director |
| Niklas Adenborg | Chief Financial Officer |
| Linda Glimberg | Chief Operating Officer |
| Kerstin Hasselgren | Senior Advisor and Head of IR |
| Charlotta Liljebris | Senior Vice President of Research and Development |
| Edward P. Jordan M.B.A. | Chief Commercial Officer |
| Anette Abrahamsson | Senior Vice President of Regulatory Affairs |
| Christer Hallgren | Senior Vice President of Intellectual Property |